Missteps could mar long-term credibility of AstraZeneca shot
LONDON (AP) — AstraZeneca’s repeated missteps in reporting vaccine data coupled with a blood clot scare could do lasting damage to the credibility of a shot that is the linchpin in the global strategy to stop the coronavirus pandemic. Experts say it could even undermine vaccine confidence more broadly. The latest stumble for the vaccine came Tuesday, when U.S. officials issued an unusual statement expressing concern that AstraZeneca had included “outdated information” when it reported encouraging results from a U.S. trial a day earlier. According to the statement, that may have provided “an incomplete view of the efficacy data.” AstraZeneca responded that the results included information through Feb. 17 but appeared to be consistent with more up-to-date data.